drug_type
RELEVANT_DRUG
intervention_type
Systemic therapy
drug_description
Anti-HER2 humanized monoclonal antibody (Herceptin) that blocks HER2 signaling and mediates ADCC; used for HER2-positive tumors.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody against HER2 (ERBB2) that binds the extracellular domain (subdomain IV), blocks HER2 signaling and receptor dimerization, inhibits downstream PI3K–AKT/MAPK pathways, and engages Fcγ receptors to mediate antibody-dependent cellular cytotoxicity (ADCC) in HER2-overexpressing tumors.
drug_name
Trastuzumab
nct_id_drug_ref
NCT06427252